The Noradrenergic System in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Nowadays it is well accepted that in Parkinson's disease (PD), the neurodegenerative process occurs in stages and that damage to other areas precedes the neuronal loss in the substantia nigra pars compacta, which is considered a pathophysiological hallmark of PD. This heterogeneous and progressive neurodegeneration may explain the diverse symptomatology of the disease, including motor and non-motor alterations. In PD, one of the first areas undergoing degeneration is the locus coeruleus (LC). This noradrenergic nucleus provides extensive innervation throughout the brain and plays a fundamental neuromodulator role, participating in stress responses, emotional memory, and control of motor, sensory, and autonomic functions. Early in the disease, LC neurons suffer modifications that can condition the effectiveness of pharmacological treatments, and importantly, can lead to the appearance of common non-motor symptomatology. The noradrenergic system also exerts anti-inflammatory and neuroprotective effect on the dopaminergic degeneration and noradrenergic damage can consequently condition the progress of the disease. From the pharmacological point of view, it is also important to understand how the noradrenergic system performs in PD, since noradrenergic medication is often used in these patients, and drug interactions can take place when combining them with the gold standard drug therapy in PD, L-3,4-dihydroxyphenylalanine (L-DOPA). This review provides an overview about the functional status of the noradrenergic system in PD and its contribution to the efficacy of pharmacological-based treatments. Based on preclinical and clinical publications, a special attention will be dedicated to the most prevalent non-motor symptoms of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Although historically the hallmark of the disease has been focused on the degeneration of the substantia nigra pars compacta (SNc), it is now well accepted that the spread of a-synuclein in the brain occurs in stages and that damage to other areas precedes the degeneration of SNc neurons, affecting glutamatergic, nora…”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“According to Braak’s theory (Braak et al., 2004), the first asynuclein aggregates in the central nervous system appear in the anterior olfactory structures and the dorsal motor nucleus of the vagus nerve, following by lower raphe system and the locus coeruleus (LC) in stage 2.”
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Aston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“…preclinical models have demonstrated the implication of the LC in arousal, cognition, anxiety, depression, pain, attention, and locomotor control (Aston-Jones and Bloom, 1981; Carter et al., 2010; Curtis et al., 2012; Sara and Bouret, 2012; Chandler et al., 2014; McCall April 2020 | Volume 11 |…”
BackgroundKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · cited 1×
“Indeed, recent publications have suggested that the a-synuclein pathology begins in the gut and travels via the vagal nerve up to the brain where it spreads following the six stages defined by Braak and colleagues (Ulusoy et al., 2013; Kim et al., 2019).”
BackgroundNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Orienting and reorienting: the locus coeruleus mediates cognition through arousal
Sara, S. J., & Bouret, S. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.011 · Cited by 1,056
Locus coeruleus and dopaminergic consolidation of everyday memory
Takeuchi, T., Duszkiewicz, A. J., Sonneborn, A., Spooner, P. A., Yamasaki, M., Watanabe, M., Smith, C. C., Fernández, G., Deisseroth, K., Greene, R. W., et al. (2016) · Nature · doi:10.1038/nature19325 · Cited by 827
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Viral-genetic tracing of the input-output organization of a central noradrenaline circuit
Schwarz, L. A., Miyamichi, K., Gao, X. J., Beier, K. T., Weissbourd, B., DeLoach, K. E., Ren, J., Ibanes, S., Malenka, R. C., Kremer, E. J., et al. (2015) · Nature · doi:10.1038/nature14600 · Cited by 744
Morón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681
Kempadoo, K. A., Mosharov, E. V., Choi, S. J., Sulzer, D., & Kandel, E. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616515114 · Cited by 647 · cited 2×
“More recently, other authors have also supported that LC activation promotes DA release in the thalamus and hippocampus, contributing to stress and cognitive functions (Smith and Greene, 2012; Kempadoo et al., 2016; Yamasaki and Takeuchi, 2017; Beas et al., 2018).”
BackgroundOrganization of the Locus Coeruleus-Norepinephrine System
Schwarz, L. A., & Luo, L. (2015) · Current Biology · doi:10.1016/j.cub.2015.09.039 · Cited by 578
Sasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., Takahashi, S., Ehara, S., Terayama, Y., & Sakai, A. (2006) · Neuroreport · doi:10.1097/01.wnr.0000227984.84927.a7 · Cited by 496 · cited 1×
“Although in vivo positron emission tomography imaging studies using non-specific ligands failed to identify the noradrenergic damage, more recent neuromelanin-sensitive magnetic resonance studies have found progressive loss of the LC signal in both idiopathic and genetic PD patients and even a lower signal in those PD…”
BackgroundHeterogeneous organization of the locus coeruleus projections to prefrontal and motor cortices
Chandler, D. J., Gao, W.-J., & Waterhouse, B. D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320827111 · Cited by 341 · cited 3×
“…depression, pain, attention, and locomotor control (Aston-Jones and Bloom, 1981; Carter et al., 2010; Curtis et al., 2012; Sara and Bouret, 2012; Chandler et al., 2014; McCall April 2020 | Volume 11 | Article 435 et al., 2015; Szot et al., 2016; Benarroch, 2017; Hirschberg et al., 2017; McCall…”
BackgroundMori, K., Ozaki, E., Zhang, B., Yang, L., Yokoyama, A., Takeda, I., Maeda, N., Sakanaka, M., & Tanaka, J. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00211-3 · Cited by 215
Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections
Ulusoy, A., Phillips, R. J., Helwig, M., Klinkenberg, M., Powley, T. L., & Di Monte, D. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1661-y · Cited by 179 · cited 1×
“This pattern of a-synuclein propagation between interconnected nuclei has also been mimicked in animal models in which a-synuclein was overexpressed by means of viral vector administration in peripheral structures (Rey et al., 2013; Ulusoy et al., 2013; Ulusoy et al., 2017; Rusconi et al., 2018).”
BackgroundAutonomic dysfunction in Parkinson's disease
Micieli, G., Tosi, P., Marcheselli, S., & Cavallini, A. (2003) · Neurological Sciences · doi:10.1007/s100720300035 · Cited by 157 · cited 1×
“Urinary and sexual dysfunctions are also late features of PD related to degeneration of brain regions that innervate the bladder, among them the LC (Micieli et al., 2003; Park and Stacy, 2009).”
BackgroundProgression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145 · cited 2×
“Consistent with LC neuron loss and degeneration, there is a decreased noradrenergic innervation of LC target structures, including the prefrontal and motor cortex, striatum, thalamus, hypothalamus, and cerebellum (Kish et al., 1984; Shannak et al., 1994; Pavese et al., 2011; Pifl et al., 2012; Sommerauer et al., 2018b…”
BackgroundLocus Coeruleus and Dopamine-Dependent Memory Consolidation
Yamasaki, M., & Takeuchi, T. (2017) · Neural Plasticity · doi:10.1155/2017/8602690 · Cited by 91
Masilamoni, G. J., Groover, O., & Smith, Y. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.025 · Cited by 37 · cited 1×
“1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys exhibit clear noradrenergic damage, including LC cell loss, lower NA concentrations in several brain regions, and reduced noradrenergic innervation of the SNc and the subthalamic nucleus (Pifl et al., 1991; Masilamoni et al., 2017).”
Background
Cited by
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Algaidi, S. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149461 · Cited by 40
Metadata
- Authors
- Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P., & Miguelez, C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-08
- Volume
- 11
- Pages
- 435-435
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3015663834
- Cited by
- 162
- References
- 23
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.